Key facts
- This page summarizes W. Bradford Smith's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 May 2026, 19:48.
W. Bradford Smith - 14 May 2026 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)
- Reporting relationship
- Director
- Issuer ticker
- LYRA
- Reported as of
- 14 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 May 2026, 19:48:25 UTC
- Prior SEC filing
- 16 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Cavalier, Attorney-in-Fact for W. Bradford Smith
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
W. Bradford Smith filed Form 4 for Lyra Therapeutics, Inc. (LYRA) on 15 May 2026.
Change
- Previous filing in this sequence was filed on 16 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001317678
Primary reporting owner
Smith W Bradford
- Relationship
- Director
- Address
- C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN
- Signature
- /s/ Jason Cavalier, Attorney-in-Fact for W. Bradford Smith
- Signature date
- 15 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LYRA
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -640
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 May 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.